News archive
Showing 692 results
December 2018
-
Media Release
Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
-
Media Release
Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
- BYL719 plus fulvestrant meaningfully prolonged PFS vs fulvestrant alone in patients with PIK3CA mutated HR+/HER2- advanced breast cancer after progression on an aromatase inhibitor or after… -
Media Release
Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
-
Media Release
Real-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies
- Promacta (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs. romiplostim, rituximab and splenectomy, in a retrospective analysis of US electronic… -
Media Release
Real-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies
-
Media Release
Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
- In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration… -
Media Release
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
-New post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patients-Crizanlizumab, a monthly infusion… -
Media Release
Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
-
Media Release
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
November 2018
-
Media Release
FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
- Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough Therapy designation for low platelet counts in people exposed to radiation- Approval based… -
Media Release
FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
-
Media Release
Novartis to fund five innovative ideas to support patients and the sickle cell community
- 2018 STEP Program™ designed to support unique proposals from nonprofit organizations that serve people living with sickle cell disease- Novartis will select proposals that demonstrate innovation in…